XML Print

Background : Lung cancer remains a major factor contributing to morbidity and mortality worldwide. Apart from the chemotherapeutic agents in routine use, factors targeting novel molecular pathways are in clinical trials and provide hope for terminal lung cancer patients. The endocannabinoid system has only recently become a popular field of study. Many experimental studies have shown that CBD and THC could be used outside of palliative care, as they play a major role in lung cancer cell apoptosis. The objective of our systematic review is to evaluate the antitumorigenic mechanisms of CBD in lung cancer cells.
Methods: We systematically searched the following databases: MEDLINE, clinicaltrials.gov, CENTRAL and google scholar using a structured algorithm. A total of 246 studies were screened and nine studies were included in the systematic review, all of which were conducted in vitro and four of which also had an in vivo component. Included studies were assessed in our review using the Toxicological data Reliability Assessment Tool (ToxRTool). Results and conclusion: The most common cell line used in all of the studies was A549, while some studies included other cell lines such as H460 and H358 as well. We concluded that CBD has direct antineoplastic effects on lung cancer cells by various mechanisms mediated by cannabinoid receptors or independent of them. All studies referred to an in vitro model so further research is required for this data to have any clinical application.

Type of Study: Review Article | Subject: Cancer Biology

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb